Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
December 08, 2022
The world desperately needs new antibiotics—and finally, the G7 is ready match commitments with action. We already found that the US would pay $17.9 billion over 30 years but save 383,000 American lives and harvest $495 billion in value. What would be the benefits to other members of the G7, and who...
Blog Post
November 28, 2022
Building on the success of Operation Warp Speed, the US should deepen its engagement and ambition in global health R&D to drive transformative improvements in global health outcomes and security. Specifically, it should consider a subscription model for new antimicrobials; an advance market commitme...
Blog Post
November 15, 2022
Congress has excellent legislation on the docket that would protect American citizens, yield huge returns, and create a safer, healthier world. We encourage the US Congress to urgently finance and authorize the PASTEUR Act, leveraging American ingenuity to boost our shared health future.
Blog Post
October 04, 2022
Most R&D money flows from the private sector, which aims to maximize returns on investment. As a result, health R&D largely skews towards rich countries’ priorities and health system technical capacities, leaving significant gaps in diseases that primarily affect poor and marginalized populations.
Blog Post
September 26, 2022
Antimicrobial resistance is a major global problem. Today, drug resistant infections kill an estimated 1.27 million people per year, and low- and middle-income countries bear the brunt of AMR-related deaths and illness. Changing how we buy antimicrobials can help solve the problem.